Moderna reports Q3 EPS 3c, consensus ($1.90)

Reports Q3 revenue $1.86B, consensus $1.25B. “During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I am pleased with the cost efficiency we achieved in the quarter, tracking ahead of where we planned to be at this time. Looking into the fourth quarter and preparing for 2025, we remain focused on driving sales growth, delivering 10 product approvals over the next three years, and continuing to reduce our cost structure,” said Stephane Bancel, Chief Executive Officer of Moderna (MRNA).